With a strong recommendation that Justin Baldoni and his team catch up on California law, Blake Lively wants the latest version of her It Ends With Us co-star’s $400 million defamation and ...
The partnership underscores Servier's commitment to developing targeted therapies that address unmet medical needs in oncology Servier will develop and commercialize BDTX-4933, a Phase 1 asset ...
Black Diamond Therapeutics has found a buyer for an early-stage targeted cancer drug, which was brushed to the side last year as it focused resources … ...
Servier will lead the development activities and the worldwide commercialization of BDTX-4933 across multiple indications. Currently, in Phase 1 development, BDTX-4933 is designed to target RAS ...
Five months after cutting support for BDTX-4933, the biotech has licensed the RAF inhibitor to Servier for $70 million upfront and up to $710 million in milestones. In October, Black Diamond ...
SURESNES, France and CAMBRIDGE, Mass., March 19, 2025 (GLOBE NEWSWIRE) -- Servier, an independent global pharmaceutical group governed by a non-profit foundation, and Black Diamond Therapeutics ...
Servier and Black Diamond Therapeutics (BDTX) announced a strategic worldwide licensing agreement for BDTX-4933, a potential best-in-class targeted therapy for solid tumors. Under this global ...
Black Diamond has got itself a longer runway, securing a licensing deal with French pharmaceutical group Servier for an early-stage small molecule cancer drug Black Diamond backburnered last year. The ...
NEW YORK – Servier has signed a global licensing agreement with Black Diamond Therapeutics to develop and commercialize BDTX-4933 for treating RAF- and RAS-mutant solid tumors, including non-small ...
Solaris Energy and Morpheus Research did not immediately respond to a Bloomberg News request for comment. Morpheus Research announced itself as a “new investigative research group dedicated to ...
Hindenburg Research founder Nathan Anderson shared his support for a new investigative research group, Morpheus Research on social media. In his post on X, formerly known as Twitter, Anderson endorsed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback